Information on pharmaceutical regulatory systems in Asian countries, collected by Ashish Katke and hosted on Harvard Dataverse. The data relates to drug approval processes, clinical trial conduct, and post-market safety monitoring. The dataset was last updated on June 19, 2026.
Use Cases
- Analyze regulatory efficiency and transparency based on country-level system descriptions
- Plan market entry strategies based on comparative data on regulatory authorities and responsibilities
- Benchmark drug approval system maturity across different Asian countries
Strengths
- Focus on Asian pharmaceutical regulatory systems, a specific regional context
- Data covers multiple aspects of the drug lifecycle from approval to post-market monitoring
Limitations
- Row count and file size are unknown, which may limit suitability assessment
- Column-level documentation is absent; field semantics must be inferred after download
Provenance
- Source
- Harvard Dataverse
- Collection Method
- Likely collected from public regulatory documents and agency information
- Freshness
- Last updated 2026-06-19 20:16:17; freshness should be verified
- Geography
- Asian countries